Fill Out Your Profile to share more about you. Learn more...

Kisqali + Femara Ups Survival for Postmeno Advanced HR+ HER2-

Options
moderators
moderators Posts: 7,966

Adding Kisqali to Femara Improves Overall Survival for Postmenopausal Women With Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer
October 5, 2021

Adding Kisqali to Femara as a first treatment for advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women improved overall survival by more than 1 year. Read more...